SAS scientists are developing biochips which are tracking the cancer
5. 8. 2016 | 2044 visits
New chips are supposed to track the chcanges of sugar component on the surface of body proteins. Theese „sweet changes“ has often a bitter aftertaste, because they are acompanioning the pathological changes for example a cancer in the body.
The scientific teams led by Ing. Jaroslav Katrlík, PhD. from the Institute of Chemistry SAS are focusing on development of the new biosensors and biochips which are detecting the changes in the sugar structures. The project BIOGLYCO is dedicated mostly to detecting changes during colon cancer, prostate cancer and scientists are beginning also with the research of this phenomenon during a breast cancer.
"Detection of changes in the structure of sugars has a great importance for research of the disease itself and its diagnosis and therapy. In addition to cancer, this phenomenon is also associated with autoimmune diseases, diabetes or Alzheimer's disease," says the leading scientist of the BIOGLYCO project Jaroslav Katrlík. The biggest challenge for scientists is currently to adjust the sensitivity of biochips properly, because many of the tracked proteins, has a low concentration in samples from patients.
Tracking changes with biochips can also help with a prognosis of illness according to scientists, because they not just signal the presence of disease, but its stage as well. Information from the biochip can also help to determine whether the current treatment works for patient, or his condition deteriorates.
The scientific teams led by Ing. Jaroslav Katrlík, PhD. from the Institute of Chemistry SAS are focusing on development of the new biosensors and biochips which are detecting the changes in the sugar structures. The project BIOGLYCO is dedicated mostly to detecting changes during colon cancer, prostate cancer and scientists are beginning also with the research of this phenomenon during a breast cancer.
"Detection of changes in the structure of sugars has a great importance for research of the disease itself and its diagnosis and therapy. In addition to cancer, this phenomenon is also associated with autoimmune diseases, diabetes or Alzheimer's disease," says the leading scientist of the BIOGLYCO project Jaroslav Katrlík. The biggest challenge for scientists is currently to adjust the sensitivity of biochips properly, because many of the tracked proteins, has a low concentration in samples from patients.
Tracking changes with biochips can also help with a prognosis of illness according to scientists, because they not just signal the presence of disease, but its stage as well. Information from the biochip can also help to determine whether the current treatment works for patient, or his condition deteriorates.